Based in the San Francisco Bay area, Altheos focuses on the development of near-clinical and clinical stage drugs for unmet medical needs. They completed a $20MM series A financing in 2010, led by Bay City Capital and with participation from Novo A/S, Canaan Partners, Life Science Angels, and Atheneos Capital. The funding will primarily support the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma, which Altheos licensed from a Japanese pharmaceutical company. The company was co-founded in 2009 by experienced pharmaceutical executives Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. Altheos is headquartered in South San Francisco and is focused on developing a best-in-class eye drop treatment for glaucoma using their lead compound, ATA907, a selective rho-kinase inhibitor.